Literature DB >> 19371348

Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings.

L Raiteri1, E Luccini, C Romei, S Salvadori, G Calò.   

Abstract

BACKGROUND AND
PURPOSE: Neuropeptide S (NPS) is a recently identified neurotransmitter/neuromodulator able to increase arousal and wakefulness while decreasing anxiety-like behaviour. As several classical transmitters play a role in arousal and anxiety, we here investigated the possible presynaptic regulation of transmitter release by NPS. EXPERIMENTAL APPROACH: Synaptosomes purified from mouse frontal cortex were prelabelled with [(3)H]5-hydroxytryptamine (5-HT), noradrenaline, dopamine, choline, D-aspartate or GABA and depolarized in superfusion with 12-15 mmol.L(-1) KCl to evoke [(3)H]neurotransmitter exocytosis. NPS was added at different concentrations (0.001 to 100 nmol.L(-1)). KEY
RESULTS: NPS behaved as an extremely potent inhibitor of the evoked overflow of [(3)H]5-HT and [(3)H]noradrenaline exhibiting EC50 values in the low picomolar range. The inhibitory action of NPS on [(3)H]5-HT release was mimicked by [Ala(2)]NPS that was, however, about 100-fold less potent than the natural peptide. NPS (up to 100 nmol.L(-1)) was unable to affect the depolarization-evoked overflow of [(3)H]D-aspartate and [(3)H]GABA. The neuropeptide only weakly reduced the overflow of [(3)H]dopamine and [(3)H]ACh when added at relatively high concentrations. CONCLUSIONS AND IMPLICATIONS: NPS, at low picomolar concentrations, can selectively inhibit the evoked release of 5-HT and noradrenaline in the frontal cortex by acting directly on 5-hydroxytryptaminergic and noradrenergic nerve terminals. These direct effects may explain only in part the unique behavioural activities of NPS, while an indirect involvement of other transmitters, especially of glutamate, must be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371348      PMCID: PMC2707993          DOI: 10.1111/j.1476-5381.2009.00163.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Functional switch from facilitation to inhibition in the control of glutamate release by metabotropic glutamate receptors.

Authors:  I Herrero; M T Miras-Portugal; J Sánchez-Prieto
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine.

Authors:  T A Paine; S L Jackman; M C Olmstead
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

Review 4.  Arousal systems.

Authors:  Barbara E Jones
Journal:  Front Biosci       Date:  2003-05-01

Review 5.  The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes.

Authors:  Craig W Berridge; Barry D Waterhouse
Journal:  Brain Res Brain Res Rev       Date:  2003-04

6.  Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala.

Authors:  Kay Jüngling; Thomas Seidenbecher; Ludmila Sosulina; Jörg Lesting; Susan Sangha; Stewart D Clark; Naoe Okamura; Dee M Duangdao; Yan-Ling Xu; Rainer K Reinscheid; Hans-Christian Pape
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

7.  The effects of neuropeptide S on ethanol drinking and other related behaviors in alcohol-preferring and -nonpreferring rats.

Authors:  Nancy E Badia-Elder; Angela N Henderson; Megan L Bertholomey; Neil C Dodge; Robert B Stewart
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

8.  Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.

Authors:  Yan-Ling Xu; Rainer K Reinscheid; Salvador Huitron-Resendiz; Stewart D Clark; Zhiwei Wang; Steven H Lin; Fernando A Brucher; Joanne Zeng; Nga K Ly; Steven J Henriksen; Luis de Lecea; Olivier Civelli
Journal:  Neuron       Date:  2004-08-19       Impact factor: 17.173

9.  Anxiolytic-like effect of neuropeptide S in the rat defensive burying.

Authors:  Giovanni Vitale; Monica Filaferro; Valentina Ruggieri; Sonia Pennella; Claudio Frigeri; Anna Rizzi; Remo Guerrini; Girolamo Calò
Journal:  Peptides       Date:  2008-08-28       Impact factor: 3.750

Review 10.  The neurobiology and control of anxious states.

Authors:  Mark J Millan
Journal:  Prog Neurobiol       Date:  2003-06       Impact factor: 11.685

View more
  12 in total

1.  Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex.

Authors:  Wei Si; Leah Aluisio; Naoe Okamura; Stewart D Clark; Ian Fraser; Steven W Sutton; Pascal Bonaventure; Rainer K Reinscheid
Journal:  J Neurochem       Date:  2010-08-30       Impact factor: 5.372

2.  Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.

Authors:  Irina A Ionescu; Julien Dine; Yi-Chun Yen; Dominik R Buell; Leonie Herrmann; Florian Holsboer; Matthias Eder; Rainer Landgraf; Ulrike Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

3.  Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice.

Authors:  Carina R Boeck; Caroline Martinello; Adalberto A de Castro; Morgana Moretti; Tiago Dos Santos Casagrande; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-19       Impact factor: 3.000

4.  Modification of caffeine effects on the affect-modulated startle by neuropeptide S receptor gene variation.

Authors:  Katharina Domschke; Benedikt Klauke; Bernward Winter; Agnes Gajewska; Martin J Herrmann; Bodo Warrings; Andreas Mühlberger; Katherina Wosnitza; Andrea Dlugos; Swantje Naunin; Kathrin Nienhaus; Manfred Fobker; Christian Jacob; Volker Arolt; Paul Pauli; Andreas Reif; Peter Zwanzger; Jürgen Deckert
Journal:  Psychopharmacology (Berl)       Date:  2012-03-08       Impact factor: 4.530

5.  Prevention of stress-impaired fear extinction through neuropeptide s action in the lateral amygdala.

Authors:  Frédéric Chauveau; Maren Denise Lange; Kay Jüngling; Jörg Lesting; Thomas Seidenbecher; Hans-Christian Pape
Journal:  Neuropsychopharmacology       Date:  2012-02-01       Impact factor: 7.853

Review 6.  Genetic polymorphism in pathogenesis of irritable bowel syndrome.

Authors:  Cynthia K Y Cheung; Justin C Y Wu
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

7.  Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders.

Authors:  Michael Camilleri; Paula Carlson; Alan R Zinsmeister; Sanna McKinzie; Irene Busciglio; Duane Burton; Marco Zucchelli; Mauro D'Amato
Journal:  Gastroenterology       Date:  2009-09-02       Impact factor: 22.682

Review 8.  The Neural Network of Neuropeptide S (NPS): Implications in Food Intake and Gastrointestinal Functions.

Authors:  Luca Botticelli; Emanuela Micioni Di Bonaventura; Massimo Ubaldi; Roberto Ciccocioppo; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-26

9.  Monoamines differentially modulate neuropeptide release from distinct sites within a single neuron pair.

Authors:  Tobias Clark; Vera Hapiak; Mitchell Oakes; Holly Mills; Richard Komuniecki
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

10.  NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.

Authors:  M Scott Bowers; Luisa P Cacheaux; Srishti U Sahu; Mary E Schmidt; Joseph A Sennello; Katherine Leaderbrand; M Amin Khan; Roger A Kroes; Joseph R Moskal
Journal:  J Neurochem       Date:  2019-10-16       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.